Dr. Verma on Advancements in Treatment of HER2-Positive Breast Cancer

Sunil Verma, MD
Published: Saturday, Mar 12, 2016



Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

One of the key advancements in the field is the understanding that treatment of HER2-positive breast cancer requires ongoing suppression of the HER2 receptor; therefore, an antibody or a tyrosine kinase inhibitor is necessary in the treatment paradigm, Verma explains. Secondly, pertuzumab in the first-line setting has been an important advance, as it demonstrates improvements in progression-free and overall survival. Additionally, T-DM1 can be used in the second-line setting and beyond to show these same benefits.

The median survival for patients with HER2-positive breast cancer exceeds 5 years, Verma says. However, critical issues that still remain include targeting patients with brain metastases and determining duration of therapies.

<<< View more from the 33rd Annual Miami Breast Cancer Conference



Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

One of the key advancements in the field is the understanding that treatment of HER2-positive breast cancer requires ongoing suppression of the HER2 receptor; therefore, an antibody or a tyrosine kinase inhibitor is necessary in the treatment paradigm, Verma explains. Secondly, pertuzumab in the first-line setting has been an important advance, as it demonstrates improvements in progression-free and overall survival. Additionally, T-DM1 can be used in the second-line setting and beyond to show these same benefits.

The median survival for patients with HER2-positive breast cancer exceeds 5 years, Verma says. However, critical issues that still remain include targeting patients with brain metastases and determining duration of therapies.

<<< View more from the 33rd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x